Abstract
The progress in genomics and proteomics resulted in increasing number of tumor-associated antigens (TAA) being discovered as cancer biomarkers and targets for immunotherapy. The key role played by HLA class I antigens in immune reactivity against malignant and virally infected cells via binding to the peptides of TAA and subsequent presentation to cytotoxic T-lymphocytes stimulates interest in the characterization of their expression in tumor cells. Various types of HLA class I alterations with different underlying molecular mechanisms are found in different malignancies. Loss or downregulation of tumor HLA class I antigen expression represents one of the main mechanisms used by cancer cells to evade immunosurveillance since it limits the ability of cytotoxic T-cell to eliminate these cells and reduces the clinical efficacy of T-cell-based cancer therapy. As a result of the immune selection, HLA class I negative variants escape and lead to tumor growth and metastatic colonization. Altered HLA class I expression on malignant cells frequently correlates with poor survival, disease progression and limited response to T-cell-based therapy. Early cancer detection and treatment require more effective cancer biomarkers, or molecular signatures, for diagnosis, prognosis, and therapeutic efficacy. Analysis of the tumor expression of HLA class I antigens as biomarkers of cancer development might help to choose an appropriate treatment protocol and monitor clinical response to cancer immunotherapy.
Keywords: HLA class I, cancer, immune escape
Current Cancer Therapy Reviews
Title: HLA Class I Expression, Tumor Escape and Cancer Progression
Volume: 4 Issue: 2
Author(s): Natalia Aptsiauri, Teresa Cabrera, Angel Garcia Lora, Francisco Ruiz-Cabello and Federico Garrido
Affiliation:
Keywords: HLA class I, cancer, immune escape
Abstract: The progress in genomics and proteomics resulted in increasing number of tumor-associated antigens (TAA) being discovered as cancer biomarkers and targets for immunotherapy. The key role played by HLA class I antigens in immune reactivity against malignant and virally infected cells via binding to the peptides of TAA and subsequent presentation to cytotoxic T-lymphocytes stimulates interest in the characterization of their expression in tumor cells. Various types of HLA class I alterations with different underlying molecular mechanisms are found in different malignancies. Loss or downregulation of tumor HLA class I antigen expression represents one of the main mechanisms used by cancer cells to evade immunosurveillance since it limits the ability of cytotoxic T-cell to eliminate these cells and reduces the clinical efficacy of T-cell-based cancer therapy. As a result of the immune selection, HLA class I negative variants escape and lead to tumor growth and metastatic colonization. Altered HLA class I expression on malignant cells frequently correlates with poor survival, disease progression and limited response to T-cell-based therapy. Early cancer detection and treatment require more effective cancer biomarkers, or molecular signatures, for diagnosis, prognosis, and therapeutic efficacy. Analysis of the tumor expression of HLA class I antigens as biomarkers of cancer development might help to choose an appropriate treatment protocol and monitor clinical response to cancer immunotherapy.
Export Options
About this article
Cite this article as:
Aptsiauri Natalia, Cabrera Teresa, Lora Garcia Angel, Ruiz-Cabello Francisco and Garrido Federico, HLA Class I Expression, Tumor Escape and Cancer Progression, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310052
DOI https://dx.doi.org/10.2174/157339408784310052 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Genetic Susceptibility to Risk for Bladder Cancer in Individuals Working in High Risk Occupations
Current Pharmacogenomics Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Predictive Biomarkers and Novel Targets in the Treatment of Metastatic Renal Cell Carcinoma
Current Medicinal Chemistry Inhibition of Carbonic Anhydrase IX: A New Strategy Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Chemopreventive Properties and Molecular Mechanisms of the Bioactive Compounds in Hibiscus Sabdariffa Linne
Current Medicinal Chemistry Sera/Organ Lysates of Selected Animals Living in Polluted Environments Exhibit Cytotoxicity against Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Interferon Therapy for Malignant Solid Tumors
Current Drug Therapy Caveolae and Caveolin-1: Novel Potential Targets for the Treatment of Cardiovascular Disease
Current Pharmaceutical Design EMT Blockage Strategies: Targeting Akt Dependent Mechanisms for Breast Cancer Metastatic Behaviour Modulation
Current Gene Therapy The Complexity of Omega-3 Fatty Acid Modulation of Signaling Pathways Related to Pancreatic Cancer
Current Medicinal Chemistry Vitamin D and Vitamin D Analogs in Cancer Treatment
Current Drug Targets Preface: [Hot topic: Metal Compounds in Medicinal Chemistry (Executive Editor: Dinorah Gambino)]
Mini-Reviews in Medicinal Chemistry Applications of HPLC-MALDI-TOF MS/MS Phosphoproteomic Analysis in Oncological Clinical Diagnostics
Current Proteomics Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets Molecular Biomarkers for Lung Adenocarcinoma: A Short Review
Current Cancer Therapy Reviews Modulation of Tumour-Related Signaling Pathways by Natural Pentacyclic Triterpenoids and their Semisynthetic Derivatives
Current Medicinal Chemistry Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry Multifunctional Proteins in Tumorigenesis: Aminoacyl-tRNA Synthetases and Translational Components
Current Proteomics Control of Neuropathic Pain by Immune Cells and Opioids
CNS & Neurological Disorders - Drug Targets Pharmacology of Ivabradine and the Effect on Chronic Heart Failure
Current Topics in Medicinal Chemistry